LivaNova PLC
LIVN
Rang in aandelen
#3790
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Aandeelprijs
$79.97
Marktkapitalisatie
$4.39B
Verandering (1 dag)
2.34%
Verandering (1 jaar)
47.82%
Land
GB
Handel LivaNova PLC (LIVN)
Categorie
Healthcare
EPS voor LivaNova PLC (LIVN)
EPS per June 2026 TTM: $3.45
Volgens de laatste financiële rapporten en de aandelenkoers van LivaNova PLC is de huidige EPS van het bedrijf (TTM) $3.45. Eind 2023 had het bedrijf een EPS van $0.33, een stijging ten opzichte van de EPS van 2022 die $-1.61 bedroeg.
EPS-geschiedenis van LivaNova PLC van 2000 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $3.45 | 194.87% |
| 2024 | $1.17 | 254.55% |
| 2023 | $0.33 | -120.50% |
| 2022 | $-1.61 | -39.93% |
| 2021 | $-2.68 | -62.04% |
| 2020 | $-7.06 | 119.25% |
| 2019 | $-3.22 | -17.65% |
| 2018 | $-3.91 | 651.92% |
| 2017 | $-0.52 | -59.69% |
| 2016 | $-1.29 | -158.90% |
| 2015 | $2.19 | 8.42% |
| 2014 | $2.02 | 20.24% |
| 2013 | $1.68 | 29.23% |
| 2012 | $1.30 | -22.16% |
| 2011 | $1.67 | -40.99% |
| 2010 | $2.83 | 183.00% |
| 2009 | $1.00 | -356.41% |
| 2008 | $-0.39 | -80.60% |
| 2007 | $-2.01 | -15.19% |
| 2006 | $-2.37 | 364.71% |
| 2005 | $-0.51 | -275.86% |
| 2004 | $0.29 | 20.83% |
| 2003 | $0.24 | -119.83% |
| 2002 | $-1.21 | 611.76% |
| 2000 | $-0.17 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $3.11 | -9.86% |
US
|
|
| $3.59 | 4.06% |
IE
|
|
| $9.73 | 182.03% |
US
|
|
| $2.48 | -28.12% |
US
|
|
| - | - |
DE
|
